Die SLK-Kliniken Heilbronn GmbH betreibt drei Krankenhäuser und eine Geriatrische Rehabilitationsklinik im [[Stadtkreis Heilbronn |Stadt-]] und Landkreis Heilbronn. Mit mehr als 4000 Mitarbeitern sind die SLK-Kliniken der größte Gesundheitsdienstleister der Region Heilbronn-Franken.

During the past decade, SLK-Kliniken Heilbronn GmbH conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 8 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 7 clinical trials were completed. i.e. 70% of trials that started reached the finish line.

Out of the total clinical trials conducted in "SLK-Kliniken Heilbronn GmbH" #1 sponsor was "University of Ulm" with 8 trials, followed by "BioNTech SE" with 2 trials sponsored, "Boston Scientific Corporation" with 2 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "SLK-Kliniken Heilbronn GmbH" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Biocompatibles UK Ltd" with 2 trials as a collaborator, "Abbott Medical Devices" with 1 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "BMBf (Federal Ministry of Education and Research)" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "SLK-Kliniken Heilbronn GmbH" are "Acute Myeloid Leukemia (AML)" (5 trials), "Acute Myeloid Leukemia" (4 trials), "Colorectal Cancer Stage II" (2 trials), "Colorectal Cancer Stage III" (2 trials) and "Malignant Melanoma" (2 trials). Many other conditions were trialed in "SLK-Kliniken Heilbronn GmbH" in a lesser frequency.

Most popular intervention types in "SLK-Kliniken Heilbronn GmbH" are "Drug" (27 trials), "Device" (6 trials), "Other" (3 trials), "Procedure" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Cytarabine" (6 trials), "Daunorubicin" (3 trials), "Dasatinib" (2 trials), "Etoposide" (2 trials) and "Gemcitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "SLK-Kliniken Heilbronn GmbH" are 37 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "SLK-Kliniken Heilbronn GmbH". undefined are not yet recruiting, 8 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in SLK-Kliniken Heilbronn GmbH, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in SLK-Kliniken Heilbronn GmbH, 3 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".

SLK-Kliniken Heilbronn GmbH has several departments that took part in Clinical trials: "SLK-Kliniken Heilbronn GmbH; Klinik für Innere Medizin III; Schwerpunkt Häma./Onko./Palliativm." - 9 trials, "Klinik Löwenstein gGmbH Med. Klinik II Onkologie" - 2 trials